RxDoctor Payments Data

John Staheli, MD

Sleep Medicine · Provo, UTNPI 1275591620

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.6% of the total across 589 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 10.8% — the pattern of someone who eats at a lot of different presentations.

$9,442in general payments, 2019–2025

Across 589 payments — averaging $16.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Harmony Biosciences LLC$1K
  • AbbVie$874
  • Jazz Pharmaceuticals Inc.$835
  • Lilly USA, LLC$833
  • Axsome Therapeutics, Inc.$681
  • AstraZeneca$604
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$8,93495%
  • Education$5085%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,442 in reported general payments places this provider in the 70th percentile of 20 sleep medicine providers in Utah.

See all sleep medicine providers in Utah

Medicare billing

Part B allowed, 2024
$297,848
Medicare patients
743
Services billed
2,466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide29$32,782
OzempicSemaglutide23$27,474
JardianceEmpagliflozin13$15,622
EliquisApixaban12$10,117
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$5,592
Gabapentin216$3,169
HumalogInsulin Lispro13$1,745
Levothyroxine Sodium142$1,723
Omeprazole111$1,597
Trazodone Hcl144$1,368
Atorvastatin Calcium100$1,325
Metformin Hcl78$1,206
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide12$1,158
Simvastatin99$1,083
Potassium Chloride52$1,069

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Humalog$833$34,52642 claims
Novo NordiskOzempic$442$27,47423 claims
Boehringer IngelheimJardiance$243$15,62213 claims
PfizerEliquis$197$10,11712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 20 sleep medicine providers in Utah.

Other sleep medicine in Provo

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →